cas 1231930-33-8|| where to buy 6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole

Название продукции:6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole

IUPAC Name:6-bromo-4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazole

: CAS：1231930-33-8; Молекулярная формула：C11H12BrFN2; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)
CM130252-5g	in stock	ƻƅƅ
CM130252-25g	in stock	ƅƏǠ
CM130252-100g	in stock	ƻșƏǠ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1231930-33-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:1231930-33-8; Молекулярная формула:C11H12BrFN2; Точка плавления:-; Smiles-код:CC2=NC1=C(F)C=C(Br)C=C1N2C(C)C; Плотность:

: Номер в каталоге:CM130252; Молекулярная масса:271.13; Точка кипения:; Номер Mdl:MFCD16660227; Хранение:Store at room temperature.

: Benzimidazoles; Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

: Abemaciclib; Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.